Healthcare professionals agree on aggressive therapy for secondary prevention of CVD with statins, the cornerstone of therapy; however, recent focus has been given to the role of inflammation in the initiation and progression of atherosclerosis, the main cause of CVD, and as a treatment target for patients at risk.